1 Baselga, J, Semiglazov, V, Manikhas, GM et al. 2007 Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (Neoadjuvant Herceptin) phase III trial Eur J Cancer 5 193.

1 Baselga, J, Semiglazov, V, Manikhas, GM et al. 2007Efficacy of neoadjuvant trastuzumab in patients with inflammatory breast cancer: data from the NOAH (Neoadjuvant Herceptin) phase III trialEur J Cancer5193.)| false
• Search Google Scholar
• Export Citation

2 Bear, HD, Anderson, S, Brown, A et al. 2003 The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165–4174.

2 Bear, HD, Anderson, S, Brown, A et al. 2003The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol214165–4174.)| false
• Search Google Scholar
• Export Citation

3 Bear, HD, Anderson, S, Smith, RE et al. 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 24 2019–2027.

3 Bear, HD, Anderson, S, Smith, RE et al. 2006Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol242019–2027.)| false
• Search Google Scholar
• Export Citation

4 Buzdar, AU, Valero, V, Ibrahim, NK et al. 2007 Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen Clin Cancer Res 13 228–233.

4 Buzdar, AU, Valero, V, Ibrahim, NK et al. 2007Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimenClin Cancer Res13228–233.)| false
• Search Google Scholar
• Export Citation

5 Capirci, C, Valentini, V, Cionini, L et al. 2008 Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients Int J Radiat Oncol Biol Phys 72 99–107.

5 Capirci, C, Valentini, V, Cionini, L et al. 2008Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patientsInt J Radiat Oncol Biol Phys7299–107.)| false
• Search Google Scholar
• Export Citation

6 Carey, LA, Dees, EC, Sawyer, L et al. 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329–2334.

6 Carey, LA, Dees, EC, Sawyer, L et al. 2007The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypesClin Cancer Res132329–2334.)| false
• Search Google Scholar
• Export Citation

7 Carey, LA, Metzger, R, Dees, EC et al. 2005 American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome J Natl Cancer Inst 97 1137–1142.

7 Carey, LA, Metzger, R, Dees, EC et al. 2005American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcomeJ Natl Cancer Inst971137–1142.)| false
• Search Google Scholar
• Export Citation

8 Chevallier, B, Roche, H, Olivier, JP et al. 1993 Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate Am J Clin Oncol 16 223–228.

8 Chevallier, B, Roche, H, Olivier, JP et al. 1993Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rateAm J Clin Oncol16223–228.)| false
• Search Google Scholar
• Export Citation

9 Dank, M, Zergenyi, E, Domotori, ZS et al. 2003 Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combination Anticancer Res 23 2879–2880.

9 Dank, M, Zergenyi, E, Domotori, ZS et al. 2003Primary systemic therapy (PST) of locally advanced breast cancer using Doxorubicin/Docetaxel combinationAnticancer Res232879–2880.)| false
• Search Google Scholar
• Export Citation

10 Feldman, LD, Hortobagyi, GN, Buzdar, AU et al. 1986 Pathological assessment of response to induction chemotherapy in breast cancer Cancer Res 46 2578–2581.

10 Feldman, LD, Hortobagyi, GN, Buzdar, AU et al. 1986Pathological assessment of response to induction chemotherapy in breast cancerCancer Res462578–2581.)| false
• Search Google Scholar
• Export Citation

11 Fisher, B, Bryant, J, Wolmark, N et al. 1998 Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 2672–2685.

11 Fisher, B, Bryant, J, Wolmark, N et al. 1998Effect of preoperative chemotherapy on the outcome of women with operable breast cancerJ Clin Oncol162672–2685.)| false
• Search Google Scholar
• Export Citation

12 Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant trastuzumab in patients with her2-positive locally advanced breast cancer: primary efficacy analysis of the noah trial. Presented at the 31st Annual San Antonio Breast Cancer Symposium, 2008 http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_1443&terms.

12 Gianni, L, Eiermann, W, Semiglazov, V, et al. Neoadjuvant trastuzumab in patients with her2-positive locally advanced breast cancer: primary efficacy analysis of the noah trial. Presented at the 31st Annual San Antonio Breast Cancer Symposium, 2008 http://www.abstracts2view.com/sabcs/view.php?nu=SABCS08L_1443&terms.)| false
• Search Google Scholar
• Export Citation

13 Gralow, JR, Burstein, HJ, Wood, W et al. 2008 Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease J Clin Oncol 26 814–819.

13 Gralow, JR, Burstein, HJ, Wood, W et al. 2008Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable diseaseJ Clin Oncol26814–819.)| false
• Search Google Scholar
• Export Citation

14 Guarneri, V, Broglio, K, Kau, SW et al. 2006 Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 1037–1044.

14 Guarneri, V, Broglio, K, Kau, SW et al. 2006Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factorsJ Clin Oncol241037–1044.)| false
• Search Google Scholar
• Export Citation

15 Hammock, L, Lewis, M, Phillips, C et al. 2003 Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization Hum Pathol 34 1043–1047.

15 Hammock, L, Lewis, M, Phillips, C et al. 2003Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridizationHum Pathol341043–1047.)| false
• Search Google Scholar
• Export Citation

16 Hayward, JL, Carbone, PP, Heusen, JC et al. 1977 Assessment of response to therapy in advanced breast cancer Br J Cancer 35 292–298.

16 Hayward, JL, Carbone, PP, Heusen, JC et al. 1977Assessment of response to therapy in advanced breast cancerBr J Cancer35292–298.)| false
• Search Google Scholar
• Export Citation

17 Hennessy, BT, Hortobagyi, GN, Rouzier, R et al. 2005 Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy J Clin Oncol 23 9304–9311.

17 Hennessy, BT, Hortobagyi, GN, Rouzier, R et al. 2005Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapyJ Clin Oncol239304–9311.)| false
• Search Google Scholar
• Export Citation

18 Heys, SD, Sarkar, T, Hutcheon, AW 2005 Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survival Breast Cancer Res Treat 90 169–185.

18 Heys, SD, Sarkar, T, Hutcheon, AW2005Primary docetaxel chemotherapy in patients with breast cancer: impact on response and survivalBreast Cancer Res Treat90169–185.)| false
• Search Google Scholar
• Export Citation

19 Kahán, Zs, Nikolényi, A, Uhercsák, G, Thurzó, L 2009 Neoadjuváns szisztémás terápia emlőrákban Orvosi Hetilap 150 65–71.

19 Kahán, Zs, Nikolényi, A, Uhercsák, G, Thurzó, L2009Neoadjuváns szisztémás terápia emlőrákbanOrvosi Hetilap15065–71.)| false
• Search Google Scholar
• Export Citation

20 Kaplan, EL, Meier, P 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457–481.

20 Kaplan, EL, Meier, P1958Nonparametric estimation from incomplete observationsJ Am Stat Assoc53457–481.)| false
• Search Google Scholar
• Export Citation

21 Kaufmann, M, Minckwitz von, G, Smith, R et al. 2003 International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations J Clin Oncol 21 2600–2608.

21 Kaufmann, M, Minckwitz von, G, Smith, R et al. 2003International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendationsJ Clin Oncol212600–2608.)| false
• Search Google Scholar
• Export Citation

22 Liedtke, C, Mazouni, C, Hess, KR et al. 2008 Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancer J Clin Oncol 26 1275–1281.

22 Liedtke, C, Mazouni, C, Hess, KR et al. 2008Response to neoadjuvant therapy and long term survival in patients with triple-negative breast cancerJ Clin Oncol261275–1281.)| false
• Search Google Scholar
• Export Citation

23 Mamounas, EP 1998 Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies Semin Oncol 25 31–35.

23 Mamounas, EP 1998 Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies Semin Oncol 25 31–35.)| false
• Search Google Scholar
• Export Citation

24 Mauri, D, Pavlidis, N, Ioannidis, JP 2005 Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis J Natl Cancer Inst 97 188–194.

24 Mauri, D, Pavlidis, N, Ioannidis, JP2005Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysisJ Natl Cancer Inst97188–194.)| false
• Search Google Scholar
• Export Citation

25 Ogston, KN, Miller, ID, Payne, S et al. 2003 A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival Breast 12 320–327.

25 Ogston, KN, Miller, ID, Payne, S et al. 2003A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survivalBreast12320–327.)| false
• Search Google Scholar
• Export Citation

26 Peintinger, F, Buzdar, AU, Kuerer, HM et al. 2008 Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab Ann Oncol 19 2020–2025.

26 Peintinger, F, Buzdar, AU, Kuerer, HM et al. 2008Hormone receptor status and pathologic response of HER2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumabAnn Oncol192020–2025.)| false
• Search Google Scholar
• Export Citation

27 Penault-Llorca, F, Abrial, C, Raoelfils, I et al. 2008 Comparison of the prognostic significance of Chevallier and Sataloff’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer Hum Pathol 39 1221–1228.

27 Penault-Llorca, F, Abrial, C, Raoelfils, I et al. 2008Comparison of the prognostic significance of Chevallier and Sataloff’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancerHum Pathol391221–1228.)| false
• Search Google Scholar
• Export Citation

28 Pinder, SE, Provenzano, E, Earl, H et al. 2007 Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy Histopathology 50 409–417.

28 Pinder, SE, Provenzano, E, Earl, H et al. 2007Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapyHistopathology50409–417.)| false
• Search Google Scholar
• Export Citation

29 Pusztai, L 2008 Preoperative systemic chemotherapy and pathologic assessment of response Pathol Oncol Res 14 169–171.

29 Pusztai, L 2008 Preoperative systemic chemotherapy and pathologic assessment of response Pathol Oncol Res 14 169–171.)| false
• Search Google Scholar
• Export Citation

30 Reis-Filho, JS, Tutt, AN 2008 Triple negative tumours: a critical review Histopathology 52 108–118.

30 Reis-Filho, JS, Tutt, AN2008Triple negative tumours: a critical reviewHistopathology52108–118.)| false
• Search Google Scholar
• Export Citation

31 Ring, AE, Ellis, PA 2002 Predictors of response to systemic therapy in breast cancer Forum (Genova) 12 19–32.

31 Ring, AE, Ellis, PA2002Predictors of response to systemic therapy in breast cancerForum (Genova)1219–32.)| false
• Search Google Scholar
• Export Citation

32 Ring, AE, Smith, IE, Ashley, S et al. 2004 Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 2012–2017.

32 Ring, AE, Smith, IE, Ashley, S et al. 2004Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancerBr J Cancer912012–2017.)| false
• Search Google Scholar
• Export Citation

33 Sanchez-Munoz, A, Garcia-Tapiador, AM, Martinez-Ortega, E et al. 2008 Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer Clin Transl Oncol 10 646–653.

33 Sanchez-Munoz, A, Garcia-Tapiador, AM, Martinez-Ortega, E et al. 2008Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancerClin Transl Oncol10646–653.)| false
• Search Google Scholar
• Export Citation

34 Sataloff, DM, Mason, BA, Prestipino, AJ et al. 1995 Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome J Am Coll Surg 180 297–306.

34 Sataloff, DM, Mason, BA, Prestipino, AJ et al. 1995Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcomeJ Am Coll Surg180297–306.)| false
• Search Google Scholar
• Export Citation

35 Straver, ME, Glas, AM, Hannemann, J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 2009.

35 Straver, ME, Glas, AM, Hannemann, J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat, 2009.)| false
• Search Google Scholar
• Export Citation

36 Straver, ME, Adrichem van, JC, Rutgers, EJ et al. 2008 Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapy Ned Tijdschr Geneeskd 152 2519–2525.

36 Straver, ME, Adrichem van, JC, Rutgers, EJ et al. 2008Neoadjuvant systemic therapy in patients with operable primary breast cancer: more benefits than breast-conserving therapyNed Tijdschr Geneeskd1522519–2525.)| false
• Search Google Scholar
• Export Citation

37 Tokes, AM, Szasz, AM, Farkas, A et al. 2009 Stromal matrix protein expression following preoperative systemic therapy in breast cancer Clin Cancer Res 15 731–739.

37 Tokes, AM, Szasz, AM, Farkas, A et al. 2009Stromal matrix protein expression following preoperative systemic therapy in breast cancerClin Cancer Res15731–739.)| false
• Search Google Scholar
• Export Citation

38 Wang, S, Yang, H, Tong, F et al. 2009 Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer Gan To Kagaku Ryoho 36 255–258.

38 Wang, S, Yang, H, Tong, F et al. 2009Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancerGan To Kagaku Ryoho36255–258.)| false
• Search Google Scholar
• Export Citation

39 Wolff, AC, Davidson, NE 2002 Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease Oncologist 7 239–245.

39 Wolff, AC, Davidson, NE2002Preoperative therapy in breast cancer: lessons from the treatment of locally advanced diseaseOncologist7239–245.)| false
• Search Google Scholar
• Export Citation

40 Wolff, AC, Hammond, ME, Schwartz, JN et al. 2007 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer J Clin Oncol 25 118–145.

40 Wolff, AC, Hammond, ME, Schwartz, JN et al. 2007American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancerJ Clin Oncol25118–145.)| false
• Search Google Scholar
• Export Citation